Madrigal Pharmaceuticals Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Madrigal Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Madrigal Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.85) by $0.53.
View Madrigal Pharmaceuticals' earnings history.

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MDGL shares have increased by 31.4% and is now trading at $106.55.
View which stocks have been most impacted by COVID-19.

9 equities research analysts have issued 12-month price targets for Madrigal Pharmaceuticals' shares. Their forecasts range from $114.00 to $204.00. On average, they expect Madrigal Pharmaceuticals' stock price to reach $168.67 in the next year. This suggests a possible upside of 58.3% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of MDGL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Madrigal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.80%), Armistice Capital LLC (2.11%), Morgan Stanley (1.59%), Rock Springs Capital Management LP (1.56%), Artisan Partners Limited Partnership (1.30%) and Dimensional Fund Advisors LP (1.04%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals.

MDGL stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Price T Rowe Associates Inc. MD, Dimensional Fund Advisors LP, Credit Suisse AG, Los Angeles Capital Management LLC, Northern Trust Corp, Occudo Quantitative Strategies LP, and SG Americas Securities LLC. Company insiders that have sold Madrigal Pharmaceuticals company stock in the last year include Bay City Capital Llc, and Fred B Craves.
View insider buying and selling activity for Madrigal Pharmaceuticals or view top insider-selling stocks.

MDGL stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, PFM Health Sciences LP, Hennion & Walsh Asset Management Inc., Armistice Capital LLC, Goldman Sachs Group Inc., Citigroup Inc., Schonfeld Strategic Advisors LLC, and Parkman Healthcare Partners LLC.
View insider buying and selling activity for Madrigal Pharmaceuticals or or view top insider-buying stocks.

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDGL stock can currently be purchased for approximately $106.55.

Madrigal Pharmaceuticals has a market capitalization of $1.77 billion. The biopharmaceutical company earns $-202,240,000.00 in net income (profit) each year or ($13.09) on an earnings per share basis.

Madrigal Pharmaceuticals employs 42 workers across the globe.

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

Madrigal Pharmaceuticals is headquartered at 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428.

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at (484) 380-9263 or via email at [email protected]